Biopharma Daily Stock Updates - 01/14/21

$XBI $153.43 (+3.27%) 📈


COVID:

$VRNA (+4.64%) - Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

https://www.veronapharma.com/media/verona-pharma-completes-enrollment-pilot-study-pmdi-ensifentrine


PIPELINE:

$ACRX (-6.53%) - AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements

https://ir.acelrx.com/news-releases/news-release-details/acelrx-announces-year-end-2020-metrics-and-review-2020


$LXRX (+105.36%) - Phase 3 clinical studies can support a new drug application (NDA) submission

http://www.lexpharma.com/media-center/news/773-lexicon-pharmaceuticals-provides-regulatory-update-on-sotagliflozin-in-heart-failure


$ALKS (+0.82%) - NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine

https://investor.alkermes.com/news-releases/news-release-details/nida-funded-study-evaluating-extended-release-injectable


$BCYC (+28.46%) - Bicycle Therapeutics Announces Pipeline Progress Update

https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-pipeline-progress-update-0


$ETON (+5.68%) - Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-acquisition-canadian-rights


$MIRM (-5.24%) - Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis

https://mirumpharma.gcs-web.com/news-releases/news-release-details/mirum-pharmaceuticals-announces-first-patient-enrolled-phase-2b


$NK (+20.37%) - NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-immunitybio-announce-positive-interim-data-survival?field_nir_news_date_value[min]=

$ONCT (+11.59%) - Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

https://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-inc-confirms-lentigen-technology-inc


$ERYP (+0.27%) - ERYTECH ANNOUNCES FIRST PATIENT ENROLLED IN A PHASE 1 INVESTIGATOR SPONSORED TRIAL OF ERYASPASE IN FIRST-LINE PANCREATIC CANCER

https://investors.erytech.com/news-releases/news-release-details/erytech-announces-first-patient-enrolled-phase-1-investigator


$ORTX (+12.52%) - Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)

https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-otl-200-granted-regenerative


$XENE (+1.83%) - Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021

https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-and


FINANCIAL:

$PRVB (-6.93%) - Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock

http://investors.proventionbio.com/2021-01-13-Provention-Bio-Announces-Pricing-of-100-Million-Public-Offering-of-Common-Stock


$RDHL (-2.38%) - RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering

https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-announces-closing-25-million-bought-deal



0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE